



Steven E. McKenzie
M.D. Ph.D.

Steven E. McKenzie has obtained his B.S.E. degree in Chemical and Engineering in 1978 at Princeton University. He has graduated and obtained M.D., Ph.D. from the University of Pennsylvania in 1985. He did his residency in Pediatrics between 1985-1988 and his fellowship in Pediatric Hematology-Oncology between 1988-1991 at the Children's Hospital of Philadelphia. He became assistant professor of Pediatrics at the School of Medicine, University of Pennsylvania in 1991, associate professor of Pediatrics, Jefferson Medical College, Thomas Jefferson University in 1996 and professor of Medicine and Pediatrics at the Thomas Jefferson University in 2000. Between 2000 and 2005 he served as Chief of Service-Hematology, Thomas Jefferson University Hospital. Between 2005 and 2012 Dr. McKenzie was Vice President for Research at the Thomas Jefferson University. In 2000 became director of the Pediatric Sickle Cell Disease Program and associate director (2000-2007), director (2007-2012) and director for translational Research (2013-) of the Cardeza Foundation Hemophilia and Thrombosis Center. Dr. McKenzie is member of several distinguished scientific societies, honorary societies, review committees and editorial boards. He is the author of 75 published original investigations as well as 22 editorials, reviews and chapters. In addition, Dr. McKenzie is actively participating in several graduate and postgraduate training programs.



INVITATION

JUNE 26-27, 2013 **MEET THE EXPERT SYMPOSIUM**

GENETICS, GENOMICS AND INDIVIDUALIZED TREATMENT FOR HEMOSTATIC DISORDERS

Organized by
„COLOMAN LAKI” Ph. D. School,
HEMOSTASIS WORKING GROUP OF THE
DEBRECEN REGIONAL CENTER OF THE
HUNGARIAN ACADEMY OF SCIENCES
DEPARTMENT OF PEDIATRIC
HEMATOLOGY-ONCOLOGY,
INSTITUTE OF PEDIATRICS,
MEDICAL AND HEALTH SCIENCE CENTER,
UNIVERSITY OF DEBRECEN

sponsored by

octapharma

for the safe and optimal use of human proteins

The symposium is supported by the TÁMOP-4.2.2/B-10/1-2010-0024 project. The project is co-financed by the European Union and the European Social Fund.

octapharma
for the safe and optimal use of human proteins




sponsored by

octapharma

for the safe and optimal use of human proteins

TÁMOP-4.2.2/B-10/1-2010-0024 PROJECT



PROGRAM

JUNE 26, WEDNESDAY

MEET THE EXPERT CONFERENCE

- 9:00 BREAKFAST MEETING WITH THE INVITED SPEAKER –
Coffee will be served
- 10:00 György Balla, László Muszbek:
WELCOME AND INTRODUCTORY REMARKS
- 10:20 Steven E. McKenzie: Genetics, genomics, and individualized
treatment for hemostatic and thrombotic disorders
- 11:00 János Kappelmayer: Modulation of platelet activation
- 11:10 Gyula Reményi, Miklós Udvardy: Coated platelets –
a subpopulation of hyperactive platelets
- 11:20 Zsuzsa Bereczky: Complex diagnostics of rare hemostasis
disorders. Focus on antithrombin deficiency
- 11:30 Csongor Kiss, Gábor Kiss, Katalin Gyurina, Zsuzsa Hevessy,
János Kappelmayer: FXIIIa as a prognostic marker in childhood
acute lymphoblastic leukemia. New biologic role for a
coagulation factor?
- 11:45 PANEL DISCUSSION.
MODERATORS: György Balla, László Muszbek
- 12:15 LUNCH BREAK



MINI SYMPOSIUM

ADVANCED CARE OF PATIENTS
WITH VON WILLEBRAND DISEASE
AND OTHER BLEEDING DISORDERS
CHAIRS: Jolán Hársfalvi, Zoltán Boda

- 13:00 Jolán Hársfalvi: Advanced diagnostic work-up of vWD and
related research activities
- 13:20 László Nemes: Nationwide overview of vWD patient care
- 13:40 Ágota Schlammadinger, István Szegedi, Zoltán Boda:
Hemophilia care in Debrecen
- 14:00 György Pfliegler: Health care requirements of patients
with rare hemostatic disorders
- 14:30 PANEL DISCUSSION
Coffee will be served



octapharma

For the safe and optimal use of human proteins

JUNE 27, THURSDAY

- 8:00 SITE VISITS
- 11:00 Steven E. McKenzie: DISCUSSION WITH Ph.D. STUDENTS
- 12:50 Csongor Kiss: CLOSING REMARKS
- 13:00 Adjourn

THE FORUM IS A REGISTERED EVENT FOR Ph.D. STUDENTS (1 CREDIT)
AND OFFTEX REGISTERED FOR LICENCED HEMATOLOGISTS,
TRANSFUSION MEDICINE SPECIALISTS AND PEDIATRICIANS

PREREGISTRATION IS REQUIRED: NOT LATER THAN JUNE 21, 2013
PREREGISTRATION E-MAIL ADDRESS: katalingyurina@gmail.com



octapharma
For the safe and optimal use of human proteins

JUNE 26-27, 2013
MEET THE EXPERT SYMPOSIUM